Hospitalists often use ondansetron as the default treatment for inpatient nausea, but a more targeted approach could improve outcomes and reduce overreliance on a single medication.
Annie Massart, an associate professor of hospital medicine at Emory University School of Medicine, presented an evidence-based framework for managing nausea during a recent conference. She explained that ondansetron’s widespread use stems from historical timing, aggressive marketing, and a lack of formal training in alternatives rather than clinical superiority.
The problem with reflex prescribing
Most physicians receive little structured education on nausea management. Ondansetron, the first serotonin antagonist approved in the 1990s, became the standard choice even when other drugs might be more effective.
Massart outlined the neuroanatomy behind nausea, linking receptors to specific pathways. The vestibular system depends on muscarinic acetylcholine and histamine-1 receptors. The gastrointestinal tract involves serotonin (5-HT3 and 5-HT4) and dopamine receptors. The brain’s vomiting center and chemoreceptor trigger zone share receptors for dopamine, neurokinin-1, and serotonin. The cerebral cortex, where nausea is perceived, also engages GABA and histamine-1 receptors.
She encouraged clinicians to move beyond automatic prescribing. Instead of defaulting to ondansetron, they should identify the likely cause of nausea and choose an antiemetic that targets the relevant pathway. Scheduled dosing often works better than as-needed administration because consistent receptor blockade prevents symptoms from returning.
Weighing risks and alternatives
A key concern with many antiemetics is QTc prolongation, which can lead to torsade de pointes, a potentially fatal arrhythmia. Massart reviewed the data, noting that a single 4-mg intravenous dose of ondansetron can extend the QTc interval by 16 to 20 milliseconds. The actual risk of torsade de pointes may be overstated, however. The 2017 American Heart Association guidelines recommend checking a baseline QTc only in patients with known risk factors, such as older age, female sex, or electrolyte imbalances.
Related: Teachers Add Spice to Classroom Lessons
Haloperidol, another common option, lost popularity after a 2007 FDA warning expanded its QTc risk label. Massart questioned this shift, arguing that the drug’s risk is similar to ondansetron’s when used at low doses. She advised keeping the total daily dose under 5 mg if monitoring is a concern.
Metoclopramide has a relatively low reported risk of QTc prolongation, with only five cases of torsade de pointes and 16 cases of prolonged QTc in the FDA’s adverse event database as of 2024. The primary concern with this drug is neurological side effects like tardive dyskinesia, which occur more frequently.
For those aiming to avoid QTc prolongation, Massart recommended oral options like aprepitant, which have minimal impact on cardiac ion channels. She also mentioned palonosetron, a second-generation serotonin antagonist with more selective receptor activity. In an unexpected finding, she cited a meta-analysis showing that inhaling isopropyl alcohol wipes—commonly used for skin preparation—can reduce nausea faster than placebo or even ondansetron.
The session ended with a key takeaway: nausea management does not need to rely on a single drug. Selecting the right medication for the cause, using scheduled dosing, and considering low-risk alternatives can lead to better outcomes. This approach may require stepping outside familiar practices.
Massart did not dismiss ondansetron entirely. She argued that a more tailored strategy could help patients avoid unnecessary side effects and achieve better symptom control. The challenge now is whether hospitalists will adopt new habits or continue using the same familiar medication.
Debates over medical treatment approaches highlight the need for evidence-based practices in healthcare.
